Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Aptamer Proteomics for Biomarker Discovery in Heart Failure with Reduced Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Long-term effects of cardiac rehabilitation after heart valve surgery - results from the randomised CopenHeartVR trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Symptoms reported in calls to emergency medical services within 24 hours prior to out-of-hospital cardiac arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cardiac Rehabilitation for Patients with Heart failure: Association With Readmission and Mortality Risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Amil M Shah
  • Brian Claggett
  • Narayana Prasad
  • Guichu Li
  • Mayra Volquez
  • Karola Jering
  • Maja Cikes
  • Attila Kovacs
  • Wilfried Mullens
  • Jose C Nicolau
  • Lars Køber
  • Peter van der Meer
  • Pardeep S Jhund
  • Ghionul Ibram
  • Martin Lefkowitz
  • Yinong Zhou
  • Scott D Solomon
  • Marc A Pfeffer
View graph of relations

BACKGROUND: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV) enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits with combined angiotensin receptor neprilysin inhibition, but human data are conflicting. The PARADISE-MI Echo Study (Prospective ARNI Versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction) tested the effect of sacubitril/valsartan compared with ramipril on LV function and adverse remodeling after high risk-AMI.

METHODS: In a prespecified substudy, 544 PARADISE-MI participants were enrolled in the Echo Study to undergo protocol echocardiography at randomization and after 8 months. Patients were randomized within 0.5 to 7 days of presentation with their index AMI to receive a target dose of sacubitril/valsartan 200 mg or ramipril 5 mg twice daily. Echocardiographic measures were performed at a core laboratory by investigators blinded to treatment assignment. The effect of treatment on change in echo measures was assessed with ANCOVA with adjustment for baseline value and enrollment region. The primary end points were change in LV ejection fraction (LVEF) and left atrial volume (LAV), and prespecified secondary end points included changes in LV end-diastolic and end-systolic volumes.

RESULTS: Mean age was 64±12 years; 26% were women; mean LVEF was 42±12%; and LAV was 49±17 mL. Of 544 enrolled patients, 457 (84%) had a follow-up echo at 8 months (228 taking sacubitril/valsartan, 229 taking ramipril). There was no significant difference in change in LVEF (P=0.79) or LAV (P =0.62) by treatment group. Patients randomized to sacubitril/valsartan demonstrated less increase in LV end-diastolic volume (P=0.025) and greater decline in LV mass index (P=0.037), increase in tissue Doppler e'lat (P=0.005), decrease in E/e'lat (P=0.045), and decrease in tricuspid regurgitation peak velocity (P=0.024) than patients randomized to ramipril. These differences remained significant after adjustment for differences in baseline characteristics. Baseline LVEF, LV end-diastolic volume, LV end-systolic volume, LV mass index, LAV, and Doppler-based diastolic indices were associated with risk of cardiovascular death or incident heart failure.

CONCLUSIONS: Treatment with sacubitril/valsartan compared with ramipril after AMI did not result in changes in LVEF or LAV at 8 months. Patients randomized to sacubitril/valsartan had less LV enlargement and greater improvement in filling pressure. Measures of LV size, systolic function, and diastolic properties were predictive of cardiovascular death and incident heart failure after AMI in this contemporary, well-treated cohort.

REGISTRATION: URL: https://www.

CLINICALTRIALS: gov; Unique identifier: NCT02924727.

Original languageEnglish
JournalCirculation
Volume146
Issue number14
Pages (from-to)1067-1081
Number of pages15
ISSN0009-7322
DOIs
Publication statusPublished - 4 Oct 2022

    Research areas

  • Aged, Aminobutyrates/adverse effects, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Biphenyl Compounds/therapeutic use, Drug Combinations, Echocardiography, Female, Heart Failure/chemically induced, Humans, Hypertrophy, Left Ventricular/drug therapy, Male, Middle Aged, Myocardial Infarction/diagnostic imaging, Neprilysin, Prospective Studies, Ramipril/pharmacology, Receptors, Angiotensin/therapeutic use, Stroke Volume/physiology, Tetrazoles/adverse effects, Valsartan/therapeutic use

ID: 84556649